We then utilized an established small molecule-specific inhibitor of RUNX1, the benzodiazepine derivative Ro5-3335, which alters the interaction between RUNX1 and CBFβ (reducing the functional activity of RUNX128) in two different protocols as an alternative therapeutic approach to gene transfer in the context of MI. The gene discussed is RUNX1; the disease is myocardial infarction.